Context: SUV measurement with 111 In-IT SPECT/CT was a very useful predictor for the therapeutic effect and grade of post-treatment neutropenia due to 90 Y-IT therapy. Background: 90 Y-labelled Ibritumomab tiuxetan ( 90 Y-IT) therapy is one of radioimmunotherapy for indolent B-cell lymphoma. 111 In-IT single photon emission computed tomography/computed tomography (SPECT/CT) is used for imaging examination to exclude ineligible cases for 90 Y-IT administration, which is actual therapeutic drug. Objective: To determine whether there is relationship between the tumor and bone marrow 111 In-IT uptake and the treatment effect and post-treatment cytopenia of 90 Y-IT therapy.
IBCL-064
Context: Duvelisib, a first-in-class oral dual PI3-kinase-d,g inhibitor, is approved for the treatment of R/R CLL/SLL after !2 prior therapies and for follicular lymphoma (FL) after !2 prior systemic therapies. DYNAMO, a phase 2 trial that evaluated the safety and efficacy of duvelisib monotherapy in iNHL, including patients with marginal zone lymphoma (MZL). Patients were double refractory to rituximab-based therapy and chemotherapy or radioimmunotherapy. Objective: To characterize efficacy and safety of duvelisib for patients with MZL from DYNAMO. Design: DYNAMO was an open-label, single-arm trial in which patients received duvelisib 25 mg BID until disease progression or unacceptable toxicity. Primary endpoint was overall response rate (ORR) as assessed by independent review committee (IRC) per revised International Working Group criteria. Secondary endpoints included duration of response, progression-free survival (PFS) and safety. Results: Of the 129 patients in DY-NAMO, 18 were of MZL histology, including 50% extranodal, 22.2% nodal, and 27.8% splenic subtypes. Median number of prior regimens was 2 (range, 1-8); 67% (n¼12) were refractory to !2 regimens. The ORR per IRC was 39% (95% CI, 17.3%-64.3%), including 1 CR (ORR by subtype: 0% extranodal, 75% nodal, 80% splenic). Median time to response was 3.7 months. As of the data cutoff (18May2018) median duration of response had not been reached. The median PFS by IRC was 15.5 months (95% CI, 3.6-27.8 months). Adverse events (AEs) were mostly grade 1/2, the most common grade !3 AEs were neutropenia (28%) and diarrhea (17%). 33% of patients discontinued duvelisib due to AE(s), including 3 who were in PR at discontinuation. Follow-up imaging is not available for 1 patient, but the other 2 had sustained responses of Abstracts S312 -Clinical Lymphoma, Myeloma & Leukemia September 2019 >1 year as of most recent imaging after treatment discontinuation. There was 1 grade 5 non-PD related AE of pancolitis (classified as potentially related to duvelisib). Conclusions: Duvelisib demonstrated clinically meaningful antitumor activity in patients with MZL. Duvelisib had a manageable safety profile, consistent with previous reports. These preliminary findings suggest that duvelisib represents a promising treatment option that warrants further investigation in patients with double-refractory MZL where limited treatment options exist. Context: Idelalisib (ZydeligÒ, IDELA) is a PI3K d inhibitor approved for treatment of relapsed or refractory (R/R) follicular lymphoma and in combination with anti-CD20 for R/R chronic lymphocytic leukemia (CLL). Objective: To evaluate the impact of IDELA treatment interruption on duration of IDELA therapy (DoT), progression-free survival (PFS) and overall survival (OS) in patients with R/R indolent non-Hodgkin's lymphoma (iNHL) and R/R CLL. Design: Retrospective analysis using data collected from patients with R/R iNHL treated with IDELA (Gopal et al., N. Engl. J. Med., 2014) or from patients with R/R CLL treated with IDELA + anti-CD20 (Furman et al., N. Engl. J. Med., 2014 and Jones et al., Lancet Haematol., 2017) . Setting: Multi-site clinical trials. Interventions: IDELA interruption for at least one treatment day due to an AE. Main Outcomes: Comparison of IDELA DoT, PFS and OS of patients stratified by number of interruptions (0, 1 or !2) and by percentage of time off therapy (0, 8% and >8%). Results: Among iNHL patients, 62 of 125 (49.6%) interrupted therapy (31.2% with 1 and 18.4% with !2 interruptions) and among CLL patients, 157 of 283 (55.5%) interrupted therapy (27.2% with 1 and 28.3% with !2 interruptions). The most common AEs (any grade) leading to interruption were diarrhea, cytopenias/febrile neutropenia, hepatic toxicity and pneumonia. Patients without treatment interruption had a shorter DoT than patients with either 1 or !2 interruptions. Patients who experienced 1 or !2 treatment interruptions achieved a longer PFS and OS than patients with no interruption. To account for differences in DoT across the interruption groups, PFS and OS were compared based on percentage of time off therapy ( 8% time off therapy and >8% time off therapy).
Patients who interrupted with time off therapy 8%, but not >8%, had improved PFS and OS compared to patients who did not interrupt. Conclusions: In these clinical studies, both iNHL and CLL patients who interrupted therapy for a limited period had longer DoT and achieved longer PFS and OS than patients who did not interrupt. The impact of intermittent IDELA therapy on clinical outcomes should be confirmed with prospective clinical studies. Keywords: idelalisib, follicular lymphoma, CLL, intermittent therapy, IBCL, indolent B-cell lymphoma Objective: We realized an update of the French national retrospective cohort of hairy cell leukemias (HCL) after 10 years of follow up, focusing on second cancers. Design: Data were collected up to June 2018 thanks to a questionnaire sent to the members of the Société Française d'Hématologie, and centralized in the cohort database. To evaluate the excess of cancers in our cohort in comparison with the French general population, we calculated the standardized incidence ratio (SIR). Results: 279 patients (pts) from 19 centers were included (median age 59 years old (29-88)). 21% had an infectious disease at diagnosis, 23% had a familial history of cancer and 11% a personal history of cancer. The median follow up
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